Lawrence Olanoff - Ironwood Pharmaceuticals Director
| IRWD Stock | USD 8.06 0.14 1.77% |
Director
Dr. Lawrence S. Olanoff, M.D. Ph.D. is an Independent Director of the Company. Dr. Olanoff most recently served as chief operating officer for Forest Laboratories, Inc. from October 2006 to December 2010. Dr. Olanoff also served as a director of Forest from October 2006 to July 2014. From July 2005 to October 2006, Dr. Olanoff was president and chief executive officer and a director at Celsion Corporation. He also served as executive vice president and chief scientific officer of Forest from 1995 to 2005. Prior to joining Forest in 1995, Dr. Olanoff served as senior vice president of clinical research and development at Sandoz Pharmaceutical Corporation and at the Upjohn Company in a number of positions including corporate vice president of clinical development and medical affairs. In addition, he is currently an adjunct assistant professor and special advisor to the president for corporate relations at the Medical University of South Carolina, an exofficio director of the MUSC Foundation for Research Development, chairman of the board of Mitochondria in Motion, a biopharmaceutical company and a board member of the Clinical Biotechnology Research Institute at Roper St. Francis Hospital, the Westedge Project, and the Zucker Institute for Applied Neurosciences, and a former board member of Axovant Sciences Ltd. and Celsion Corporation since 2015.
| Age | 66 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 100 Summer Street, Boston, MA, United States, 02110 |
| Phone | 617 621 7722 |
| Web | https://www.ironwoodpharma.com |
Ironwood Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1339 % which means that it generated a profit of $0.1339 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.7404) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Garen Bohlin | Collegium Pharmaceutical | 70 | |
| Edward Benz | Deciphera Pharmaceuticals LLC | 71 | |
| Heather Mason | Assertio Therapeutics | 64 | |
| Yvonne Greenstreet | Pacira Pharmaceuticals | 55 | |
| Steven Ratoff | Eagle Pharmaceuticals | 81 | |
| Richard Lerner | Intracellular Th | 79 | |
| David Anstice | Alkermes Plc | 69 | |
| Wendy Dixon | Alkermes Plc | 62 | |
| Richard Koo | Amphastar P | 77 | |
| Stephen Shohet | Amphastar P | 82 | |
| Peter Lankau | ANI Pharmaceuticals | 60 | |
| Alfred Sandrock | Neurocrine Biosciences | 60 | |
| Andreas Wicki | Pacira Pharmaceuticals | 59 | |
| Nancy Snyderman | Alkermes Plc | 66 | |
| David Nash | ANI Pharmaceuticals | 62 | |
| George Morrow | Neurocrine Biosciences | 66 | |
| Christopher Alafi | Intracellular Th | 54 | |
| Mark McGovern | Esperion Therapeutics | 65 | |
| Stephen Sherwin | Neurocrine Biosciences | 69 | |
| Sander Flaum | Eagle Pharmaceuticals | 81 | |
| Paul Hastings | Pacira Pharmaceuticals | 58 | |
Management Performance
| Return On Equity | -6.74 | ||||
| Return On Asset | 0.13 |
Ironwood Pharmaceuticals Leadership Team
Elected by the shareholders, the Ironwood Pharmaceuticals' board of directors comprises two types of representatives: Ironwood Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ironwood. The board's role is to monitor Ironwood Pharmaceuticals' management team and ensure that shareholders' interests are well served. Ironwood Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ironwood Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie McHugh, Independent Director | ||
| Jana Noeldeke, Basel Leader | ||
| Christopher Wright, Senior Vice President - Global Development and Chief Development Officer | ||
| Christopher Walsh, Independent Director | ||
| Ronald Silver, Corporate Officer | ||
| Thomas McCourt, Chief Commercial Officer and Sr. VP of Marketing and Sales | ||
| Lawrence Olanoff, Director | ||
| Sravan Emany, Principal VP | ||
| Mark Mallon, CEO, Director | ||
| Jason Rickard, VP COO | ||
| Halley Gilbert, Senior Vice President Chief Legal Officer, Secretary | ||
| Matt Roache, Director Relations | ||
| Andrew Dreyfus, Director | ||
| Douglas Williams, Director | ||
| Mike Nanfito, Vice Excellence | ||
| William Huyett, COO | ||
| Edward Owens, Independent Director | ||
| Amy Schulman, Director | ||
| Michael MD, Senior Officer | ||
| George Conrades, Independent Director | ||
| Terrance McGuire, Independent Director | ||
| Meredith Kaya, Director - Investor Relations | ||
| Marla Kessler, Director | ||
| Marcel Moulaison, Vice Operations | ||
| Beth Calitri, Head Relations | ||
| Marsha Fanucci, Independent Director | ||
| Peter Hecht, Co-Founder, CEO and Director | ||
| Catherine Moukheibir, Director | ||
| Kelly MacDonald, Chief Accounting Officer, Vice President - Finance | ||
| Mark Currie, Chief Scientific Officer, Sr. VP and President of RandD | ||
| Gina Consylman, Interim CFO | ||
| John Minardo, Chief VP | ||
| Jon Duane, Director | ||
| Thomas Graney, CFO and Sr. VP of Fin. and Corporate Strategy | ||
| Greg Martini, Vice Relations | ||
| Bryan Roberts, Independent Chairman of the Board | ||
| MPH MD, VP Development |
Ironwood Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ironwood Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.74 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | (2.26) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 1.86 B | ||||
| Shares Outstanding | 156.53 M | ||||
| Shares Owned By Insiders | 2.07 % | ||||
| Shares Owned By Institutions | 97.93 % | ||||
| Number Of Shares Shorted | 21.95 M | ||||
| Price To Earning | 18.35 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.69) | Earnings Share (6.45) | Revenue Per Share 2.848 | Quarterly Revenue Growth 0.097 | Return On Assets 0.1339 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.